Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2011 1
2013 1
2014 3
2015 4
2016 2
2017 2
2018 6
2019 6
2020 10
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG).
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino KI, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda SE, Okamoto M, Yoshimoto Y, Okada S, Ibe H, Oguma E, Goto S; CITEG. Takimoto R, et al. Among authors: kitahara m. Cytotherapy. 2023 Nov;25(11):1229-1235. doi: 10.1016/j.jcyt.2023.06.007. Epub 2023 Jul 22. Cytotherapy. 2023. PMID: 37486281 Free article.
Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
Yamada K, Mizukoshi E, Seike T, Horii R, Terashima T, Iida N, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Takamura T, Harada K, Kaneko S. Yamada K, et al. Among authors: kitahara m. J Gastroenterol Hepatol. 2019 Oct;34(10):1829-1835. doi: 10.1111/jgh.14654. Epub 2019 Apr 7. J Gastroenterol Hepatol. 2019. PMID: 30864239
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T, Yamashita T, Takata N, Takeda Y, Kido H, Iida N, Kitahara M, Shimakami T, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Terashima T, et al. Among authors: kitahara m. Hepatol Res. 2021 Feb;51(2):190-200. doi: 10.1111/hepr.13588. Epub 2020 Dec 4. Hepatol Res. 2021. PMID: 33197087
37 results